Late-stage clinical trials rarely deliver neat storylines. But across Europe’s trial networks in 2025, a few readouts pointed in the same direction: toward treatments built to modify disease biology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback